Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE

BACKGROUND: In the pivotal phase III 2-year ADVANCE study, subcutaneous peginterferon beta-1a 125 mcg every 2 weeks demonstrated significant improvements in clinical outcomes, including disability endpoints, in patients with relapsing–remitting multiple sclerosis (RRMS). Here, we aim to further eval...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Neurol Disord
Autors principals: Newsome, Scott D., Kieseier, Bernd C., Liu, Shifang, You, Xiaojun, Kinter, Elizabeth, Hung, Serena, Sperling, Bjoern
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400156/
https://ncbi.nlm.nih.gov/pubmed/28450894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616676065
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars